Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study

References

• Srivastava SP, Goodwin JE. Cancer biology and prevention in diabetes. Cells. 2020;9(6):1380. doi:10.3390/cells9061380
   PubMed Web of Science ®Google Scholar
• Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Front Immunol. 2020;11:1582. doi:10.3389/fimmu.2020.01582
   PubMed Web of Science ®Google Scholar
• Papazafiropoulou AK, Koros C, Melidonis A, Antonopoulos S. Diabetes and dementia - the two faces of Janus. Arch Med Sci Atheroscler Dis. 2020;5:e186–e197. doi:10.5114/amsad.2020.97433
   PubMedGoogle Scholar
• Dalle S, Koppo K. Is inflammatory signaling involved in disease-related muscle wasting? Evidence from osteoarthritis, chronic obstructive pulmonary disease and type II diabetes. Exp Gerontol. 2020;137:110964. doi:10.1016/j.exger.2020.110964
   PubMed Web of Science ®Google Scholar
• Khateeb J, Fuchs E, Khamaisi M. Diabetes and lung disease: a neglected relationship. Rev Diabet Stud. 2019;15:1–15. doi:10.1900/RDS.2019.15.1
   PubMedGoogle Scholar
• Diaconu C, Salmen T, Gaman MA, et al. SGLT2 inhibition in patients with type 2 diabetes and cardiovascular diseases: which are the benefits? Rom J Mil Med. 2019;CXXII(1):16–21.
   Google Scholar
• Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2012;30(4):368–402. doi:10.1080/10590501.2012.735519
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471. doi:10.1056/NEJMoa072761
   PubMed Web of Science ®Google Scholar
• Tseng CH, Huang TS. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese diabetic patients. Diabetes Res Clin Pract. 2005;70(2):193–194. doi:10.1016/j.diabres.2004.11.003
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al.; for PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289. doi:10.1016/S0140-6736(05)67528-9
   PubMed Web of Science ®Google Scholar
• Kernan WN, Viscoli CM, Furie KL, et al.; for IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14):1321–1331. doi:10.1056/NEJMoa1506930
   PubMed Web of Science ®Google Scholar
• Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916–922. doi:10.2337/dc10-1068
   PubMed Web of Science ®Google Scholar
• Hampp C, Pippins J. Pioglitazone and bladder cancer: FDA’s assessment. Pharmacoepidemiol Drug Saf. 2017;26(2):117–118. doi:10.1002/pds.4154
   PubMed Web of Science ®Google Scholar
• Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia. 2011;54(8):2009–2015. doi:10.1007/s00125-011-2171-z
   PubMed Web of Science ®Google Scholar
• Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012;35(2):278–280. doi:10.2337/dc11-1449
   PubMed Web of Science ®Google Scholar
• Tseng CH. Rosiglitazone is not associated with an increased risk of bladder cancer. Cancer Epidemiol. 2013;37(4):385–389. doi:10.1016/j.canep.2013.03.013
   PubMed Web of Science ®Google Scholar
• Tseng CH. Pioglitazone and lung cancer risk in Taiwanese patients with type 2 diabetes. Diabetes Metab. 2018;44(1):77–79. doi:10.1016/j.diabet.2017.05.011
   PubMed Web of Science ®Google Scholar
• Sekine Y, Katsura H, Koh E, Hiroshima K, Fujisawa T. Early detection of COPD is important for lung cancer surveillance. Eur Respir J. 2012;39(5):1230–1240. doi:10.1183/09031936.00126011
   PubMed Web of Science ®Google Scholar
• Kutsukake M, Matsutani T, Tamura K, et al. Pioglitazone attenuates lung injury by modulating adipose inflammation. J Surg Res. 2014;189(2):295–303. doi:10.1016/j.jss.2014.03.007
   PubMed Web of Science ®Google Scholar
• Hong Y, Kim YS, Hong SH, Oh YM. Therapeutic effects of adipose-derived stem cells pretreated with pioglitazone in an emphysema mouse model. Exp Mol Med. 2016;48(10):e266. doi:10.1038/emm.2016.93
   PubMed Web of Science ®Google Scholar
• Park JS, Kim HK, Kang EY, Cho R, Oh YM. Potential therapeutic strategy in chronic obstructive pulmonary disease using pioglitazone-augmented Wharton’s jelly-derived mesenchymal stem cells. Tuberc Respir Dis. 2019;82(2):158–165. doi:10.4046/trd.2018.0044
   PubMed Web of Science ®Google Scholar
• Lea S, Plumb J, Metcalfe H, et al. The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD. Eur Respir J. 2014;43(2):409–420. doi:10.1183/09031936.00187812
   PubMed Web of Science ®Google Scholar
• Shan M, You R, Yuan X, et al. Agonistic induction of PPARγ reverses cigarette smoke-induced emphysema. J Clin Invest. 2014;124(3):1371–1381. doi:10.1172/JCI70587
   PubMed Web of Science ®Google Scholar
• Rinne ST, Liu CF, Feemster LC, et al. Thiazolidinediones are associated with a reduced risk of COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2015;10:1591–1597. doi:10.2147/COPD.S82643
   PubMed Web of Science ®Google Scholar
• Parsons LS. Performing a 1:N case-control match on propensity score. Available from: http://www2.sas.com/proceedings/sugi29/165-29.pdf. Accessed December 8, 2021.
   Google Scholar
• Tseng CH. Metformin decreases risk of tuberculosis infection in type 2 diabetes patients. J Clin Med. 2018;7(9):264. doi:10.3390/jcm7090264
   PubMed Web of Science ®Google Scholar
• Tseng CH. Metformin use is associated with a lower risk of osteoporosis/vertebral fracture in Taiwanese patients with type 2 diabetes mellitus. Eur J Endocrinol. 2021;184(2):299–310. doi:10.1530/EJE-20-0507
   PubMed Web of Science ®Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679. doi:10.1002/sim.6607
   PubMed Web of Science ®Google Scholar
• Chen KY, Wu SM, Tseng CH, et al. Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerbations in new-onset COPD patients with advanced diabetic mellitus: a cohort-based case-control study. BMC Pulm Med. 2021;21(1):141. doi:10.1186/s12890-021-01505-7
   PubMed Web of Science ®Google Scholar
• Rehan VK, Torday JS. PPARγ Signaling mediates the evolution, development, homeostasis, and repair of the lung. PPAR Res. 2012;2012:289867. doi:10.1155/2012/289867
   PubMed Web of Science ®Google Scholar
• Lee C, Sakurai R, Shin E, Wang Y, Liu J, Rehan VK. Antenatal PPAR-γ agonist pioglitazone stimulates fetal lung maturation equally in males and females. Am J Physiol Lung Cell Mol Physiol. 2020;319(3):L435–L443. doi:10.1152/ajplung.00376.2018
   PubMed Web of Science ®Google Scholar
• Kesmodel US. Information bias in epidemiological studies with a special focus on obstetrics and gynecology. Acta Obstet Gynecol Scand. 2018;97(4):417–423. doi:10.1111/aogs.13330
   PubMed Web of Science ®Google Scholar
• Montazeri RS, Fatahi S, Sohouli MH, et al. The effect of nigella sativa on biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials. J Food Biochem. 2021;45(4):e13625. doi:10.1111/jfbc.13625
   PubMed Web of Science ®Google Scholar
• Pourrajab B, Fatahi S, Sohouli MH, Găman MA, Shidfar F. The effects of probiotic/synbiotic supplementation compared to placebo on biomarkers of oxidative stress in adults: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2022;62:490–507. doi:10.1080/10408398.2020.1821166
   PubMed Web of Science ®Google Scholar
• Egbuna C, Awuchi CG, Kushwaha G, et al. Bioactive compounds effective against type 2 diabetes mellitus: a systematic review. Curr Top Med Chem. 2021;21(12):1067–1095. doi:10.2174/1568026621666210509161059
   PubMed Web of Science ®Google Scholar
• Găman MA, Dobrică EC, Cozma MA, et al. Crosstalk of magnesium and serum lipids in dyslipidemia and associated disorders: a systematic review. Nutrients. 2021;13(5):1411. doi:10.3390/nu13051411
   PubMed Web of Science ®Google Scholar
• Crismaru I, Pantea Stoian A, Bratu OG, et al. Low-density lipoprotein cholesterol lowering treatment: the current approach. Lipids Health Dis. 2020;19(1):85. doi:10.1186/s12944-020-01275-x
   PubMed Web of Science ®Google Scholar
• Dobrică EC, Găman MA, Cozma MA, Bratu OG, Pantea Stoian A, Diaconu CC. Polypharmacy in type 2 diabetes mellitus: insights from an internal medicine department. Medicina. 2019;55(8):436. doi:10.3390/medicina55080436
   PubMed Web of Science ®Google Scholar